[Lithium carbonate--a preventive agent against leukopenia during cytostatic therapy].
A group of 51 patients treated surgically for ovarian carcinoma was randomly subdivided to test the efficacy of lithium carbonate in the prevention of leucopenia during systemic chemotherapy. In 26 patients receiving sequential lithium carbonate the side effect of myelosuppression was mitigated and the leucocyte count during treatment, which determines the dosage of the cytostatic drugs, was significantly higher in this group. It was, thus, possible to reduce the number of cytostatic courses of treatment in the lithium group in comparison with the treatment courses in the 25 control patients. Lithium therapy had to be discontinued due to side effects in seven patients, which were then excluded from the trial.
D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000517:prevention & control*; D008094:Lithium / Q000009:adverse effects / Q000627:therapeutic use*; D016651:Lithium Carbonate; D010051:Ovarian Neoplasms / Q000188:drug therapy; D014202:Tremor / Q000139:chemically induced
D016651:Lithium Carbonate; D004317:Doxorubicin; D003520:Cyclophosphamide; D008094:Lithium
Lithiumkarbonat--ein Prophylaktikum gegen Leukopenien bei zytostatischer Therapie.